<sentence id="0">Lymphocyte glucocorticoid receptor : predictor of sertraline response in adolescent major depressive disorder ( MDD ) .</sentence>
<sentence id="1">Major depressive disorder ( MDD ) in adolescents demonstrates resistance to tricyclic antidepressants and absence of hypercortisolemia .</sentence>
<sentence id="2"><scope type="spec" id="0"> The efficacy of serotonin reuptake inhibitors ( SRIs ) is <cue type="spec" id="0">uncertain</cue></scope> , and response predictors are unavailable .</sentence>
<sentence id="3">Abnormal fast feedback and negative feedback of the hypothalamic-pituitary-adrenal axis implicates a dampened limbic-hippocampal glucocorticoid type II receptor ( GCII ) .</sentence>
<sentence id="4">We <scope type="spec" id="1"> <cue type="spec" id="1">hypothesized</cue> that lymphocyte GCII is altered in adolescent MDD</scope> and could serve as a marker for response to SRIs .</sentence>
<sentence id="5">In an open-label study , adolescents ( n = 20 ) meeting DSM-III-R criteria for MDD showed baseline lymphocyte GCII sites per cell ( sites/cell ) values of 793 +/- 106 versus 2,563 +/- 499 ( +/- SEM ) for matched controls ( n = 18 ) ( t = 3.5 ; df = 36 ; p < .001 ) .</sentence>
<sentence id="6">GCII was bimodally distributed , with SRI responders differing from nonresponders ( t = 3.9 ; df = 14 ; p < .001 ) .</sentence>
<sentence id="7">GCII accurately classified 90 percent of sertraline responders and 80 percent of nonresponders .</sentence>
<sentence id="8">Only SRI responders showed GCII sites/cell upregulated after 6 weeks of treatment ( t = 2.1 , df = 10 ; p < .05 ) .</sentence>